Alteogen Healthcare and Altos Biologics Merge

Official Launch Under the New Name "Alteogen Biologics"
Aiming for Eylea Biosimilar Approval and Licensing Agreements

Alteogen announced on May 22 that its subsidiaries, Alteogen Healthcare and Altos Biologics, have officially launched as a single integrated corporation under the new name "Alteogen Biologics."

Alteogen Biologics

According to Alteogen Biologics, this merger is a strategic decision aimed at maximizing synergy between Alteogen Healthcare, which possesses capabilities in pharmaceutical distribution, sales, and marketing, and Altos Biologics, which has expertise in clinical development and a new drug pipeline.

Alteogen Healthcare distributes adhesion barrier agents, growth hormones, and "Teragaseju," the first recombinant hyaluronidase product in Korea. Altos Biologics has successfully completed global Phase 3 clinical trials for an Eylea biosimilar and is currently undergoing domestic and European (EMA) regulatory approval processes. In addition, it has a new pipeline with "OP-01," a bispecific antibody-based biobetter for ophthalmic diseases, which is being developed in-house.

The merged entity, Alteogen Biologics, will maintain a co-CEO system to leverage its expertise, with representatives from both Alteogen Healthcare and Altos Biologics overseeing their respective business divisions.

Chief Executive Officer Ji Heejung stated, "We will strengthen our clinical and regulatory affairs capabilities established through the development of the Eylea biosimilar, expand Teragase indications, and secure a global new drug pipeline including OP-01."

Chief Executive Officer Ko Jinkook explained the marketing strategy, saying, "We plan to pursue customized sales strategies and various global partnerships to facilitate Teragase's entry into major domestic hospitals, expand overseas, and promote global sales of the Eylea biosimilar."